Novo Nordisk Pharmatech to open new sales office in US

In 2021, Novo Nordisk Pharmatech will open up a US sales office. With this, the firm will have representation in Denmark, Singapore and the US.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk Pharmatech, which is Danish pharmaceutical giant Novo Nordisk's supply-focused subsidiary, will establish a new sales office in the US in the course of 2021, according to the firm's annual report for 2020, in which the firm reveals that it will open up a sales office in Boston in the middle of this year.

Novo Nordisk Pharmatech's CEO Rasmus Hother le Fevre tells MedWatch that this is to ensure that the best possible service is provided to the firm's customers.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs